AMRN Share Price

Open 3.25 Change Price %
High 3.28 1 Day -0.06 -1.82
Low 3.13 1 Week 0.15 4.85
Close 3.24 1 Month 0.32 10.96
Volume 1286184 1 Year 1.40 76.09
52 Week High 3.65
52 Week Low 0.00
AMRN Important Levels
Resistance 2 3.38
Resistance 1 3.32
Pivot 3.22
Support 1 3.16
Support 2 3.10
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.45 7.29%
MU 20.45 7.29%
MU 20.45 7.29%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ANTH 2.03 38.10%
EMKR 8.45 31.01%
MBLX 0.32 28.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 8.00 23.08%
ATEA 1.95 21.88%
ATEA 1.95 21.88%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
QKLS 0.12 -36.84%
More..

Amarin Corporation PLC (NASDAQ: AMRN)

AMRN Technical Analysis 4
As on 7th Dec 2016 AMRN Share Price closed @ 3.24 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 2.29 & Buy for SHORT-TERM with Stoploss of 3.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMRN Target for December
1st Target up-side 3.71
2nd Target up-side 4.04
3rd Target up-side 4.37
1st Target down-side 2.77
2nd Target down-side 2.44
3rd Target down-side 2.11
AMRN Other Details
Segment EQ
Market Capital 1595353216.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.amarincorp.com
AMRN Address
AMRN
2 Pembroke House
Upper Pembroke Street 28-32
Dublin, 2
Ireland
Phone: 353 1 669 9020
Interactive Technical Analysis Chart Amarin Corporation PLC ( AMRN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Amarin Corporation PLC
AMRN Business Profile
Amarin Corporation plc (Amarin), incorporated on March 1, 1989, is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial). The MARINE trial is conducted with omega-3 fatty acids in treating patients with very high triglycerides, is a Phase-III, multi-center, placebo-controlled, randomized, double-blind, 12-week study. Patients enrolled in the MARINE trial were given the option to be treated with AMR101 for a period of up to 40-weeks after their last dose in the pivotal trial. The ANCHOR trial is a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal study in patients with high triglycerides who were on optimized statin therapy. In April 2011, it reported top-line results from the ANCHOR trial. Prior to commencing the MARINE and ANCHOR trials, it conducted a pre-clinical program for AMR101, including toxicology and pharmacology studies. In addition to the MARINE and ANCHOR trials, it completed a 28-day pharmacokinetic study. It is also focusing development of other compounds based on its internal lipid science expertise.